{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:19:00Z","timestamp":1792685940997,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-06075-5","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T14:57:01Z","timestamp":1763132221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bispecific antibodies in metastatic castration-resistant prostate cancer: therapeutic strategies and frontier advances"],"prefix":"10.1007","volume":"43","author":[{"given":"Jia Wei","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi Xuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"6075_CR1","doi-asserted-by":"crossref","first-page":"175628722311822","DOI":"10.1177\/17562872231182219","volume":"15","author":"KK Zarrabi","year":"2023","unstructured":"Zarrabi KK, Narayan V, Mille PJ, Zibelman MR, Miron B, Bashir B, Kelly WK (2023) Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer. Ther Adv Urol 15:17562872231182220","journal-title":"Ther Adv Urol"},{"issue":"1","key":"6075_CR2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2159-8290.CD-23-0984","volume":"14","author":"O Nolan-Stevaux","year":"2024","unstructured":"Nolan-Stevaux O, Li C, Liang L, Zhan J, Estrada J, Osgood T, Li F, Zhang H, Case R, Murawsky CM, Estes B, Moore GL, Bernett MJ, Muchhal U, Desjarlais JR, Staley BK, Stevens J, Cooke KS, Aeffner F, Thomas O, Bailis JM (2024) AMG 509 (Xaluritamig), an anti-STEAP1 XmAb 2+1 T-cell redirecting immune therapy with avidity-dependent activity against prostate cancer. Cancer Discov 14(1):90\u2013103","journal-title":"Cancer Discov"},{"issue":"10","key":"6075_CR3","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1158\/1078-0432.CCR-21-0355","volume":"27","author":"NV Kamat","year":"2021","unstructured":"Kamat NV, Yu EY, Lee JK (2021) BiTE-ing into prostate cancer with bispecific T-cell engagers. Clin Cancer Res 27(10):2675\u20132677","journal-title":"Clin Cancer Res"},{"issue":"11","key":"6075_CR4","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1021\/acsptsci.3c00159","volume":"6","author":"G Das","year":"2023","unstructured":"Das G, Ptacek J, Havlinova B, Nedvedova J, Barinka C, Novakova Z (2023) Targeting prostate cancer using bispecific T-cell engagers against prostate-specific membrane antigen. ACS Pharmacol Transl Sci 6(11):1703\u20131714","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"5","key":"6075_CR5","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/2326-6066.CIR-19-0518","volume":"8","author":"D Chiu","year":"2020","unstructured":"Chiu D, Tavar\u00e9 R, Haber L, Aina OH, Vazzana K, Ram P, Danton M, Finney J, Jalal S, Krueger P, Giurleo JT, Ma D, Smith E, Thurston G, Kirshner JR, Crawford A (2020) A PSMA-targeting CD3 bispecific antibody induces antitumor responses that are enhanced by 4\u20131BB costimulation. Cancer Immunol Res 8(5):596\u2013608","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"6075_CR6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-23-1230","volume":"14","author":"C Hage Chehade","year":"2024","unstructured":"Hage Chehade C, Gebrael G, Agarwal N (2024) Bispecific T-cell engagers in metastatic castration-resistant prostate cancer. Cancer Discov 14(1):20\u201322","journal-title":"Cancer Discov"},{"issue":"1","key":"6075_CR7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1158\/1078-0432.CCR-22-1601","volume":"29","author":"UN Vaishampayan","year":"2023","unstructured":"Vaishampayan UN, Thakur A, Chen W, Deol A, Patel M, Dobson K, Dickow B, Schalk D, Schienschang A, Whitaker S, Polend A, Fontana JA, Heath EI, Lum LG (2023) Phase II trial of pembrolizumab and anti-CD3 x anti-HER2 bispecific antibody-armed activated T cells in metastatic castration-resistant prostate cancer. Clin Cancer Res 29(1):122\u2013133","journal-title":"Clin Cancer Res"},{"issue":"10","key":"6075_CR8","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-20-3725","volume":"27","author":"P Deegen","year":"2021","unstructured":"Deegen P, Thomas O, Nolan-Stevaux O, Li S, Wahl J, Bogner P, Aeffner F, Friedrich M, Liao MZ, Matthes K, Rau D, Rattel B, Raum T, Kufer P, Coxon A, Bailis JM (2021) The PSMA-targeting half-life extended BiTE therapy AMG 160 has potent antitumor activity in preclinical models of metastatic castration-resistant prostate cancer. Clin Cancer Res 27(10):2928\u20132937","journal-title":"Clin Cancer Res"},{"issue":"9","key":"6075_CR9","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1158\/1535-7163.MCT-15-0242","volume":"15","author":"G Hernandez-Hoyos","year":"2016","unstructured":"Hernandez-Hoyos G, Sewell T, Bader R, Bannink J, Chenault RA, Daugherty M, Dasovich M, Fang H, Gottschalk R, Kumer J, Miller RE, Ravikumar P, Wiens J, Algate PA, Bienvenue D, McMahan CJ, Natarajan SK, Gross JA, Blankenship JW (2016) MOR209\/ES414, a novel bispecific antibody targeting PSMA for the treatment of metastatic castration-resistant prostate cancer. Mol Cancer Ther 15(9):2155\u20132165","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"6075_CR10","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11307-014-0772-x","volume":"17","author":"CM van Rij","year":"2015","unstructured":"van Rij CM, Frielink C, Goldenberg DM, Sharkey RM, Franssen GM, L\u00fctje S, McBride WJ, Oyen WJ, Boerman OC (2015) Pretargeted immunoPET of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody in mice with PC3 xenografts. Mol Imaging Biol 17(1):94\u2013101","journal-title":"Mol Imaging Biol"},{"issue":"12","key":"6075_CR11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/protein\/gzx058","volume":"30","author":"NL Goicochea","year":"2017","unstructured":"Goicochea NL, Garnovskaya M, Blanton MG, Chan G, Weisbart R, Lilly MB (2017) Development of cell-penetrating bispecific antibodies targeting the N-terminal domain of androgen receptor for prostate cancer therapy. Protein Eng Des Select PEDS 30(12):785\u2013793","journal-title":"Protein Eng Des Select PEDS"},{"issue":"3","key":"6075_CR12","volume":"20","author":"G Das","year":"2025","unstructured":"Das G, Ptacek J, Campbell J, Li X, Havlinova B, Noonepalle SK, Villagra A, Barinka C, Novakova Z (2025) Targeting prostate cancer by new bispecific monocyte engager directed to prostate-specific membrane antigen. PLoS ONE 20(3):e0307353","journal-title":"PLoS ONE"},{"issue":"1","key":"6075_CR13","first-page":"79","volume":"24","author":"T Schwaab","year":"2001","unstructured":"Schwaab T, Lewis LD, Cole BF, Deo Y, Fanger MW, Wallace P, Guyre PM, Kaufman PA, Heaney JA, Schned AR, Harris RD, Ernstoff MS (2001) Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2\/neu) in patients whose prostate cancer overexpresses HER-2\/neu. J Immunother (Hagerstown, Md\u202f: 1997) 24(1):79\u201387","journal-title":"J Immunother (Hagerstown, Md : 1997)"},{"issue":"1","key":"6075_CR14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1042\/BJ20120433","volume":"445","author":"K Yamamoto","year":"2012","unstructured":"Yamamoto K, Trad A, Baumgart A, H\u00fcske L, Lorenzen I, Chalaris A, Gr\u00f6tzinger J, Dechow T, Scheller J, Rose-John S (2012) A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells. Biochem J 445(1):135\u2013144","journal-title":"Biochem J"},{"issue":"12","key":"6075_CR15","volume":"27","author":"LA King","year":"2024","unstructured":"King LA, Veth M, Iglesias-Guimarais V, Blijdorp I, Kloosterman J, Vis AN, Roovers RC, Hulsik DL, Riedl T, Adang AEP, Parren PWHI, van Helden PM, de Gruijl TD, van der Vliet HJ (2024) Leveraging V\u03b39V\u03b42 T cells against prostate cancer through a VHH-based PSMA-V\u03b42 bispecific T cell engager. iScience 27(12):111289","journal-title":"iScience"},{"key":"6075_CR16","doi-asserted-by":"crossref","first-page":"1399802","DOI":"10.3389\/fphar.2024.1399802","volume":"15","author":"H Lampe","year":"2024","unstructured":"Lampe H, Tam L, Hansen AR (2024) Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future. Front Pharmacol 15:1399802","journal-title":"Front Pharmacol"},{"issue":"3","key":"6075_CR17","volume":"13","author":"Y Sun","year":"2025","unstructured":"Sun Y, Zhou L, Gu X, Zhao J, Bi J, Pan L (2025) Leveraging T cell co-stimulation for enhanced therapeutic efficacy of trispecific antibodies targeting prostate cancer. J Immunother Cancer 13(3):e010140","journal-title":"J Immunother Cancer"},{"issue":"1","key":"6075_CR18","doi-asserted-by":"crossref","first-page":"2356820","DOI":"10.1080\/15384047.2024.2356820","volume":"25","author":"J Palecki","year":"2024","unstructured":"Palecki J, Bhasin A, Bernstein A, Mille PJ, Tester WJ, Kelly WK, Zarrabi KK (2024) T-cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer. Cancer Biol Ther 25(1):2356820","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"6075_CR19","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.clgc.2023.02.010","volume":"21","author":"EA Lim","year":"2023","unstructured":"Lim EA, Schweizer MT, Chi KN, Aggarwal R, Agarwal N, Gulley J, Attiyeh E, Greger J, Wu S, Jaiprasart P, Loffredo J, Bandyopadhyay N, Xie H, Hansen AR (2023) Phase 1 study of safety and preliminary clinical activity of JNJ-63898081, a PSMA and CD3 bispecific antibody, for metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 21(3):366\u2013375","journal-title":"Clin Genitourin Cancer"},{"key":"6075_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00120-025-02574-w","author":"S Jung","year":"2025","unstructured":"Jung S, Heitmann J, Pfl\u00fcgler M, Jung G, Rausch S, Salih H (2025) Bispezifische Antik\u00f6rper in der Therapie des Prostatakarzinoms [Bispecific antibodies in prostate cancer therapy]. Urologie (Heidelberg, Germany). https:\/\/doi.org\/10.1007\/s00120-025-02574-w","journal-title":"Urologie (Heidelberg, Germany)"},{"issue":"2","key":"6075_CR21","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201911902","volume":"13","author":"L Zekri","year":"2021","unstructured":"Zekri L, Vogt F, Osburg L, M\u00fcller S, Kauer J, Manz T, Pfl\u00fcgler M, Maurer A, Heitmann JS, Hagelstein I, M\u00e4rklin M, H\u00f6rner S, Todenh\u00f6fer T, Calaminus C, Stenzl A, Pichler B, la Foug\u00e8re C, Schneider MA, Rammensee HG, Zender L, Jung G (2021) An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer. EMBO Mol Med 13(2):e11902","journal-title":"EMBO Mol Med"},{"issue":"4","key":"6075_CR22","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.7150\/ijbs.96155","volume":"21","author":"K Hushmandi","year":"2025","unstructured":"Hushmandi K, Einollahi B, Lee EHC, Sakaizawa R, Glaviano A, Reiter RJ, Saadat SH, Farani MR, Huh YS, Aref AR, Salimimoghadam S, Kumar AP (2025) Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: recent innovations based on preclinical and clinical evidence. Int J Biol Sci 21(4):1410\u20131435","journal-title":"Int J Biol Sci"},{"issue":"9","key":"6075_CR23","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00259-013-2434-7","volume":"40","author":"CM van Rij","year":"2013","unstructured":"van Rij CM, L\u00fctje S, Frielink C, Sharkey RM, Goldenberg DM, Franssen GM, McBride WJ, Rossi EA, Oyen WJ, Boerman OC (2013) Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. Eur J Nucl Med Mol Imaging 40(9):1377\u20131383","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6075_CR24","doi-asserted-by":"crossref","first-page":"1261070","DOI":"10.3389\/fimmu.2023.1261070","volume":"14","author":"HL Penny","year":"2023","unstructured":"Penny HL, Hainline K, Theoharis N, Wu B, Brandl C, Webhofer C, McComb M, Wittemer-Rump S, Koca G, Stienen S, Bargou RC, Hummel HD, Loidl W, Gr\u00fcllich C, Eggert T, Tran B, Mytych DT (2023) Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy. Front Immunol 14:1261070","journal-title":"Front Immunol"},{"key":"6075_CR25","doi-asserted-by":"crossref","first-page":"175883592110538","DOI":"10.1177\/17588359211053898","volume":"13","author":"AL Giraudet","year":"2021","unstructured":"Giraudet AL, Kryza D, Hofman M, Moreau A, Fizazi K, Flechon A, Hicks RJ, Tran B (2021) PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going? Ther Adv Med Oncol 13:17588359211053898","journal-title":"Ther Adv Med Oncol"},{"issue":"549","key":"6075_CR26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba2325","volume":"12","author":"JC Waite","year":"2020","unstructured":"Waite JC, Wang B, Haber L, Hermann A, Ullman E, Ye X, Dudgeon D, Slim R, Ajithdoss DK, Godin SJ, Ramos I, Wu Q, Oswald E, Poon P, Golubov J, Grote D, Stella J, Pawashe A, Finney J, Herlihy E, Skokos D (2020) Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy. Sci Transl Med 12(549):eaba2325","journal-title":"Sci Transl Med"},{"issue":"7","key":"6075_CR27","first-page":"685","volume":"62","author":"M Krebs","year":"2023","unstructured":"Krebs M, Chatterjee M, K\u00fcbler H, Kalogirou C (2023) Neue Formen der Immuntherapie f\u00fcr die Uroonkologie\u202f: HLA-unabh\u00e4ngige Therapieans\u00e4tze mit bispezifischen Antik\u00f6rpern und CAR-T-Zellen [New forms of immunotherapy in uro-oncology\u202f: HLA-independent therapeutic approaches with bispecific antibodies and CAR T cells]. Urologie (Heidelberg, Germany) 62(7):685\u2013690","journal-title":"Urologie (Heidelberg, Germany)"},{"issue":"3","key":"6075_CR28","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s10637-023-01367-2","volume":"41","author":"L Ma","year":"2023","unstructured":"Ma L, Ma J, Sun X, Liu H (2023) Bispecific anti-CD3\u00d7anti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies. Invest New Drugs 41(3):522\u2013531","journal-title":"Invest New Drugs"},{"issue":"2","key":"6075_CR29","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1158\/0008-5472.CAN-22-1433","volume":"83","author":"J Chou","year":"2023","unstructured":"Chou J, Egusa EA, Wang S, Badura ML, Lee F, Bidkar AP, Zhu J, Shenoy T, Trepka K, Robinson TM, Steri V, Huang J, Wang Y, Small EJ, Chan E, Stohr BA, Ashworth A, Delafontaine B, Rottey S, Cooke KS, Aggarwal R (2023) Immunotherapeutic targeting and PET imaging of DLL3 in small-cell neuroendocrine prostate cancer. Cancer Res 83(2):301\u2013315","journal-title":"Cancer Res"},{"issue":"6","key":"6075_CR30","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.4049\/jimmunol.1200341","volume":"189","author":"A Feldmann","year":"2012","unstructured":"Feldmann A, Arndt C, T\u00f6pfer K, Stamova S, Krone F, Cartellieri M, Koristka S, Michalk I, Lindemann D, Schmitz M, Temme A, Bornh\u00e4user M, Ehninger G, Bachmann M (2012) Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells. J Immunol 189(6):3249\u20133259","journal-title":"J Immunol"},{"issue":"33","key":"6075_CR31","volume":"7","author":"SC Lee","year":"2021","unstructured":"Lee SC, Ma JSY, Kim MS, Laborda E, Choi SH, Hampton EN, Yun H, Nunez V, Muldong MT, Wu CN, Ma W, Kulidjian AA, Kane CJ, Klyushnichenko V, Woods AK, Joseph SB, Petrassi M, Wisler J, Li J, Jamieson CAM, Young TS (2021) A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand. Sci Adv 7(33):eabi8193","journal-title":"Sci Adv"},{"issue":"6","key":"6075_CR32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002488","volume":"9","author":"K Dang","year":"2021","unstructured":"Dang K, Castello G, Clarke SC, Li Y, Balasubramani A, Boudreau A, Davison L, Harris KE, Pham D, Sankaran P, Ugamraj HS, Deng R, Kwek S, Starzinski A, Iyer S, van Schooten W, Schellenberger U, Sun W, Trinklein ND, Buelow R, Dalvi P (2021) Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release. J Immunother Cancer 9(6):e002488","journal-title":"J Immunother Cancer"},{"issue":"12","key":"6075_CR33","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1158\/1535-7163.MCT-12-0042","volume":"11","author":"M Friedrich","year":"2012","unstructured":"Friedrich M, Raum T, Lutterbuese R, Voelkel M, Deegen P, Rau D, Kischel R, Hoffmann P, Brandl C, Schuhmacher J, Mueller P, Finnern R, Fuergut M, Zopf D, Slootstra JW, Baeuerle PA, Rattel B, Kufer P (2012) Regression of human prostate cancer xenografts in mice by AMG 212\/BAY2010112, a novel PSMA\/CD3-bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol Cancer Ther 11(12):2664\u20132673","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"6075_CR34","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1186\/s12885-020-07562-1","volume":"20","author":"ME Lund","year":"2020","unstructured":"Lund ME, Howard CB, Thurecht KJ, Campbell DH, Mahler SM, Walsh BJ (2020) A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells. BMC Cancer 20(1):1214","journal-title":"BMC Cancer"},{"issue":"8","key":"6075_CR35","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978","volume":"30","author":"T Dorff","year":"2024","unstructured":"Dorff T, Horvath LG, Autio K, Bernard-Tessier A, Rettig MB, Machiels JP, Bilen MA, Lolkema MP, Adra N, Rottey S, Greil R, Matsubara N, Tan DSW, Wong A, Uemura H, Lemech C, Meran J, Yu Y, Minocha M, McComb M, Tran B (2024) A phase I study of Acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer. Clin Cancer Res 30(8):1488\u20131500","journal-title":"Clin Cancer Res"},{"issue":"2","key":"6075_CR36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2217\/imt-2020-0256","volume":"13","author":"HD Hummel","year":"2021","unstructured":"Hummel HD, Kufer P, Gr\u00fcllich C, Seggewiss-Bernhardt R, Deschler-Baier B, Chatterjee M, Goebeler ME, Miller K, de Santis M, Loidl W, Dittrich C, Buck A, Lapa C, Thurner A, Wittemer-Rump S, Koca G, Boix O, D\u00f6cke WD, Finnern R, Kusi H, Bargou RC (2021) Pasotuxizumab, a BiTE\u00ae immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings. Immunotherapy 13(2):125\u2013141","journal-title":"Immunotherapy"},{"issue":"10","key":"6075_CR37","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3109\/1061186X.2013.818675","volume":"21","author":"V Patil","year":"2013","unstructured":"Patil V, Gada K, Panwar R, Majewski S, Tekabe Y, Varvarigou A, Khaw BA (2013) In vitro demonstration of enhanced prostate cancer toxicity: pretargeting with Bombesin bispecific complexes and targeting with polymer-drug-conjugates. J Drug Target 21(10):1012\u20131021","journal-title":"J Drug Target"},{"key":"6075_CR38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12976-015-0010-5","volume":"12","author":"CH Hao","year":"2015","unstructured":"Hao CH, Han QH, Shan ZJ, Hu JT, Zhang N, Zhang XP (2015) Effects of different interchain linkers on biological activity of an anti-prostate cancer single-chain bispecific antibody. Theor Biol Med Model 12:14","journal-title":"Theor Biol Med Model"},{"issue":"1","key":"6075_CR39","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae313","volume":"30","author":"E Calvo","year":"2025","unstructured":"Calvo E, Doger B, Carles J, Peer A, Sarid D, Eigl BJ, Avadhani A, Yao D, Lin V, Wu S, Jaiprasart P, Loffredo J, Tamegnon M, Xu W, Xie H, Hansen AR (2025) A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer. Oncologist 30(1):oyae313","journal-title":"Oncologist"},{"issue":"44","key":"6075_CR40","doi-asserted-by":"crossref","first-page":"17796","DOI":"10.1073\/pnas.1316026110","volume":"110","author":"CH Kim","year":"2013","unstructured":"Kim CH, Axup JY, Lawson BR, Yun H, Tardif V, Choi SH, Zhou Q, Dubrovska A, Biroc SL, Marsden R, Pinstaff J, Smider VV, Schultz PG (2013) Bispecific small molecule-antibody conjugate targeting prostate cancer. Proc Natl Acad Sci U S A 110(44):17796\u201317801","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"6075_CR41","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s00259-011-2050-3","volume":"39","author":"V Patil","year":"2012","unstructured":"Patil V, Gada K, Panwar R, Varvarigou A, Majewski S, Weisenberger A, Ferris C, Tekabe Y, Khaw BA (2012) Imaging small human prostate cancer xenografts after pretargeting with bispecific bombesin-antibody complexes and targeting with high specific radioactivity labeled polymer-drug conjugates. Eur J Nucl Med Mol Imaging 39(5):824\u2013839","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"6075_CR42","first-page":"323","volume":"29","author":"CM van Rij","year":"2014","unstructured":"van Rij CM, Frielink C, Goldenberg DM, Sharkey RM, L\u00fctje S, McBride WJ, Oyen WJ, Boerman OC (2014) Pretargeted radioimmunotherapy of prostate cancer with an anti-TROP-2\u00d7anti-HSG bispecific antibody and a (177)Lu-labeled peptide. Cancer Biother Radiopharm 29(8):323\u2013329","journal-title":"Cancer Biother Radiopharm"},{"issue":"1","key":"6075_CR43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1158\/1541-7786.MCR-19-0442","volume":"18","author":"R Joshi","year":"2020","unstructured":"Joshi R, Ren W, Mathew P (2020) A bispecific antibody targeting the \u03b1v and \u03b15\u03b21 integrins induces integrin degradation in prostate cancer cells and is superior to monospecific antibodies. Molecular cancer research\u202f: MCR 18(1):27\u201332","journal-title":"Molecular cancer research : MCR"},{"issue":"2","key":"6075_CR44","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1054\/bjoc.2001.1878","volume":"85","author":"ND James","year":"2001","unstructured":"James ND, Atherton PJ, Jones J, Howie AJ, Tchekmedyian S, Curnow RT (2001) A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer. Br J Cancer 85(2):152\u2013156","journal-title":"Br J Cancer"},{"issue":"24","key":"6075_CR45","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1016\/j.bmcl.2017.09.065","volume":"27","author":"JT Patterson","year":"2017","unstructured":"Patterson JT, Isaacson J, Kerwin L, Atassi G, Duggal R, Bresson D, Zhu T, Zhou H, Fu Y, Kaufmann GF (2017) PSMA-targeted bispecific Fab conjugates that engage T cells. Bioorg Med Chem Lett 27(24):5490\u20135495","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"6075_CR46","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s12885-020-07058-y","volume":"20","author":"MJ Bou-Dargham","year":"2020","unstructured":"Bou-Dargham MJ, Sha L, Sang QA, Zhang J (2020) Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy. BMC Cancer 20(1):572","journal-title":"BMC Cancer"},{"key":"6075_CR47","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3389\/fonc.2019.00884","volume":"9","author":"AN Boettcher","year":"2019","unstructured":"Boettcher AN, Usman A, Morgans A, VanderWeele DJ, Sosman J, Wu JD (2019) Past, current, and future of immunotherapies for prostate cancer. Front Oncol 9:884","journal-title":"Front Oncol"},{"issue":"15_suppl","key":"6075_CR48","volume":"39","author":"JS De Bono","year":"2021","unstructured":"De Bono JS, Fong L, Beer TM et al (2021) Results of an ongoing phase 1\/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 39(15_suppl):5013","journal-title":"J Clin Oncol"},{"issue":"3","key":"6075_CR49","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030549","volume":"13","author":"JS Heitmann","year":"2021","unstructured":"Heitmann JS, Pfluegler M, Jung G, Salih HR (2021) Bispecific antibodies in prostate cancer therapy: current status and perspectives. Cancers (Basel) 13(3):549","journal-title":"Cancers (Basel)"},{"key":"6075_CR50","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40259-020-00465-4","volume":"35","author":"NL Jarvi","year":"2021","unstructured":"Jarvi NL, Balu-Iyer SV (2021) Immunogenicity challenges associated with subcutaneous delivery of therapeutic proteins. BioDrugs 35:125\u2013146","journal-title":"BioDrugs"},{"key":"6075_CR51","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/imr.12393","volume":"270","author":"M Klinger","year":"2016","unstructured":"Klinger M, Benjamin J, Kischel R, Stienen S, Zugmaier G (2016) Harnessing T cells to fight cancer with BiTE(R) antibody constructs - past developments and future directions. Immunol Rev 270:193\u2013208","journal-title":"Immunol Rev"},{"key":"6075_CR52","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","volume":"24","author":"J Stultz","year":"2021","unstructured":"Stultz J, Fong L (2021) How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis 24:697\u2013717","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"6075_CR53","doi-asserted-by":"crossref","first-page":"S507","DOI":"10.1016\/j.annonc.2020.08.869","volume":"31","author":"B Tran","year":"2020","unstructured":"Tran B, Horvath L, Dorff T et al (2020) 609O results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE\u00ae) immune therapy for metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol 31:S507","journal-title":"Ann Oncol"},{"key":"6075_CR54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS5590","author":"B Tran","year":"2020","unstructured":"Tran B, Horvath L, Rettig M et al (2020) Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate - specific membrane antigen, in patients with metastatic castration - resistant prostate cancer (mCRPC). J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.TPS5590","journal-title":"J Clin Oncol"},{"issue":"2","key":"6075_CR55","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P (2019) Epidemiology of prostate cancer. World J Oncol 10(2):63\u201389. https:\/\/doi.org\/10.14740\/wjon1191","journal-title":"World J Oncol"},{"key":"6075_CR56","unstructured":"Rosario E, Rosario DJ (2023). Localized prostate cancer. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing"},{"issue":"2","key":"6075_CR57","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 79(2):243\u2013262. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.042","journal-title":"Eur Urol"},{"issue":"6","key":"6075_CR58","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1097\/JU.0000000000001313","volume":"204","author":"M Maggi","year":"2020","unstructured":"Maggi M, Cowan JE, Fasulo V, Washington SL, Lonergan PE, Sciarra A, Nguyen HG, Carroll PR (2020) The long-term risks of metastases in men on active surveillance for early stage prostate cancer. J Urol 204(6):1222\u20131228. https:\/\/doi.org\/10.1097\/JU.0000000000001313","journal-title":"J Urol"},{"issue":"3","key":"6075_CR59","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3978\/j.issn.2223-4683.2015.05.02","volume":"4","author":"T Chandrasekar","year":"2015","unstructured":"Chandrasekar T, Yang JC, Gao AC, Evans CP (2015) Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol 4(3):365\u2013380. https:\/\/doi.org\/10.3978\/j.issn.2223-4683.2015.05.02","journal-title":"Transl Androl Urol"},{"issue":"3","key":"6075_CR60","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.2246","volume":"5","author":"MM Desai","year":"2022","unstructured":"Desai MM, Cacciamani GE, Gill K, Zhang J, Liu L, Abreu A, Gill IS (2022) Trends in incidence of metastatic prostate cancer in the US. JAMA Netw Open 5(3):e222246. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.2246","journal-title":"JAMA Netw Open"},{"issue":"3","key":"6075_CR61","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00259-021-05550-6","volume":"49","author":"M Bauckneht","year":"2022","unstructured":"Bauckneht M, Rebuzzi SE, Signori A, Frantellizzi V, Murianni V, Lodi Rizzini E, Mascia M, Lavelli V, Donegani MI, Ponzano M et al (2022) The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study). Eur J Nucl Med Mol Imaging 49(3):1063\u20131074. https:\/\/doi.org\/10.1007\/s00259-021-05550-6","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"6075_CR62","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.euf.2017.11.009","volume":"5","author":"PG Corn","year":"2019","unstructured":"Corn PG, Agarwal N, Araujo JC, Sonpavde G (2019) Taxane-based combination therapies for metastatic prostate cancer. Eur Urol Focus 5(3):369\u2013380. https:\/\/doi.org\/10.1016\/j.euf.2017.11.009","journal-title":"Eur Urol Focus"},{"issue":"9","key":"6075_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092187","volume":"13","author":"S Venkatachalam","year":"2021","unstructured":"Venkatachalam S, McFarland TR, Agarwal N, Swami U (2021) Immune checkpoint inhibitors in prostate cancer. Cancers (Basel) 13(9):2187. https:\/\/doi.org\/10.3390\/cancers13092187","journal-title":"Cancers (Basel)"},{"issue":"4","key":"6075_CR64","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.3390\/curroncol30040323","volume":"30","author":"SM Lanka","year":"2023","unstructured":"Lanka SM, Zorko NA, Antonarakis ES, Barata PC (2023) Metastatic castration-resistant prostate cancer, immune checkpoint inhibitors, and beyond. Curr Oncol 30(4):4246\u20134256. https:\/\/doi.org\/10.3390\/curroncol30040323","journal-title":"Curr Oncol"},{"issue":"5","key":"6075_CR65","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3390\/cancers15051412","volume":"15","author":"DC Sim\u00e3o","year":"2023","unstructured":"Sim\u00e3o DC, Zarrabi KK, Mendes JL, Luz R, Garcia JA, Kelly WK, Barata PC (2023) Bispecific T-cell engagers therapies in solid tumors: focusing on prostate cancer. Cancers 15(5):1412. https:\/\/doi.org\/10.3390\/cancers15051412","journal-title":"Cancers"},{"issue":"4","key":"6075_CR66","first-page":"197","volume":"36","author":"E Anassi","year":"2011","unstructured":"Anassi E, Ndefo UA (2011) Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. P T 36(4):197\u2013202","journal-title":"P T"},{"issue":"10","key":"6075_CR67","doi-asserted-by":"publisher","first-page":"907","DOI":"10.2217\/fon-2017-0531","volume":"14","author":"CE Handy","year":"2018","unstructured":"Handy CE, Antonarakis ES (2018) Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol 14(10):907\u2013917. https:\/\/doi.org\/10.2217\/fon-2017-0531","journal-title":"Future Oncol"},{"issue":"3","key":"6075_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030503","volume":"14","author":"MPJ Perera","year":"2022","unstructured":"Perera MPJ, Thomas PB, Risbridger GP, Taylor R, Azad A, Hofman MS, Williams ED, Vela I (2022) Chimeric antigen receptor T-cell therapy in metastatic castrate-resistant prostate cancer. Cancers (Basel) 14(3):503. https:\/\/doi.org\/10.3390\/cancers14030503","journal-title":"Cancers (Basel)"},{"issue":"4","key":"6075_CR69","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41591-022-01742-1","volume":"28","author":"NP Tschernia","year":"2022","unstructured":"Tschernia NP, Norberg SM, Gulley JL (2022) CAR T cells reach clinical milestone in prostate cancer. Nat Med 28(4):635\u2013636. https:\/\/doi.org\/10.1038\/s41591-022-01742-1","journal-title":"Nat Med"},{"issue":"1","key":"6075_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0741-7","volume":"7","author":"G Schepisi","year":"2019","unstructured":"Schepisi G, Cursano MC, Casadei C, Menna C, Altavilla A, Lolli C, Cerchione C, Paganelli G, Santini D, Tonini G et al (2019) CAR-T cell therapy: a potential new strategy against prostate cancer. J Immunother Cancer 7(1):258. https:\/\/doi.org\/10.1186\/s40425-019-0741-7","journal-title":"J Immunother Cancer"},{"issue":"9","key":"6075_CR71","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41585-021-00488-8","volume":"18","author":"P Wolf","year":"2021","unstructured":"Wolf P, Alzubi J, Gratzke C, Cathomen T (2021) The potential of CAR T cell therapy for prostate cancer. Nat Rev Urol 18(9):556\u2013571. https:\/\/doi.org\/10.1038\/s41585-021-00488-8","journal-title":"Nat Rev Urol"},{"key":"6075_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhu L, Zhang H, Chen S, Xiao Y (2022) CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol 13:927153. https:\/\/doi.org\/10.3389\/fimmu.2022.927153","journal-title":"Front Immunol"},{"issue":"4","key":"6075_CR73","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan V, Barber-Rotenberg JS, Jung I-Y, Lacey SF, Rech AJ, Davis MM, Hwang W-T, Lal P, Carpenter EL, Maude SL et al (2022) PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med 28(4):724\u2013734. https:\/\/doi.org\/10.1038\/s41591-022-01726-1","journal-title":"Nat Med"},{"issue":"6_suppl","key":"6075_CR74","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1200\/JCO.2022.40.6_suppl.098","volume":"40","author":"SF Slovin","year":"2022","unstructured":"Slovin SF, Dorff TB, Falchook GS, Wei XX, Gao X, McKay RR, Oh DY, Wibmer AG, Spear MA, McCaigue J et al (2022) Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 40(6_suppl):98\u201398. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.098","journal-title":"J Clin Oncol"},{"issue":"1","key":"6075_CR75","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","volume":"14","author":"Z Tian","year":"2021","unstructured":"Tian Z, Liu M, Zhang Y, Wang X (2021) Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol 14(1):75. https:\/\/doi.org\/10.1186\/s13045-021-01084-4","journal-title":"J Hematol Oncol"},{"issue":"18","key":"6075_CR76","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.3390\/cancers15184550","volume":"15","author":"MH Omer","year":"2023","unstructured":"Omer MH, Shafqat A, Ahmad O, Alkattan K, Yaqinuddin A, Damlaj M (2023) Bispecific antibodies in hematological malignancies: a scoping review. Cancers Basel 15(18):4550. https:\/\/doi.org\/10.3390\/cancers15184550","journal-title":"Cancers Basel"},{"issue":"3","key":"6075_CR77","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/icb.2014.93","volume":"93","author":"AM Huehls","year":"2015","unstructured":"Huehls AM, Coupet TA, Sentman CL (2015) Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol 93(3):290\u2013296. https:\/\/doi.org\/10.1038\/icb.2014.93","journal-title":"Immunol Cell Biol"},{"issue":"14","key":"6075_CR78","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1002\/cncr.32909","volume":"126","author":"H Einsele","year":"2020","unstructured":"Einsele H, Borghaei H, Orlowski RZ, Subklewe M, Roboz GJ, Zugmaier G, Kufer P, Iskander K, Kantarjian HM (2020) The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer 126(14):3192\u20133201. https:\/\/doi.org\/10.1002\/cncr.32909","journal-title":"Cancer"},{"issue":"8","key":"6075_CR79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183390","volume":"12","author":"SL Ross","year":"2017","unstructured":"Ross SL, Sherman M, McElroy PL, Lofgren JA, Moody G, Baeuerle PA, Coxon A, Arvedson T (2017) Bispecific T cell engager (BiTE\u00ae) antibody constructs can mediate bystander tumor cell killing. PLoS ONE 12(8):e0183390. https:\/\/doi.org\/10.1371\/journal.pone.0183390","journal-title":"PLoS ONE"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-06075-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-06075-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-06075-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:04:29Z","timestamp":1767999869000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-06075-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6075"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-06075-5","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study does not need ethical approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"694"}}